Skip to main content

A phase IIb, double-blind, randomized, active controlled, multicentre, non-inferiority trial followed by a phase III, single-arm, open-label trial to assess immunogenicity and safety of a booster vaccination with a recombinant protein rbd fusion dimer candidate (PHH-1V) against sars-cov-2 in adults fully vaccinated against covid-19.

VHIR Annual Report 2022